Unlike TNIIIA2, which has the ability to activate β1-integrins and is involved in the aggressive development of cancer, FNIII14, the peptide containing the bioactive site of plasma fibronectin, demonstrated an anti-tumor effect [329]. This evidence concerns the gene FN1 and neoplasm.